Klin Farmakol Farm. 2015;29(4):144-147

Direct oral anticoagulants in the therapy of venous thromboembolism

Petr Dulíček
IV. interní hematologická klinika, FN a LF v Hradci Králové

Heparin and antagonists of vitamin K were therapy of choice of venous thromboembolism for many years.

Nowadays we can also use in therapy direct anticoagulants which make treatment more comfotable not only for patients, but also for

doctors. In the article, we discuss therapy of thrombosis with all new three anticoagulants.

Keywords: venous thromboembolism, outpatient therapy, DOACs Klin Farmakol Farm 2015; 29(3): 144–147 Tabulka 1. Srovnání vlastností antitrombotik Vlastnosti kumariny UFH LMWH Fondaparinux Působení vit. K dep.f. více KF více KF nepřímý inhibitor F Xa Podání per os s.c. s.c. s.c. Dávkování 1× d. dle INR kontinuálně i.v. 1× d. (event. 2x d.) 1x denně Nástup plného účinku 72–96 hodin 20 minut 2 hodiny 2 hodiny Biologická dostupnost 100 % variabilní 80–90 % 100 % Biologický poločas 40 hodin dle dávky: 1–1,5 h in vitro 4–7 hodin 17 hodin Antidotum koncetrát PCC – protrombinový komplex protamin sulfát částečná eliminace protamin sulfátem není Místo eliminace – vylučování játra ledviny, RES ledviny ledviny Monitorování ano-INR ano-aPTT ne (někdy ano – antiXa) ne (někdy ano) antiXa Lékové interakce četné ano ano ne *KF – koagulační faktor

Published: January 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dulíček P. Direct oral anticoagulants in the therapy of venous thromboembolism. Klin Farmakol Farm. 2015;29(4):144-147.
Download citation

References

  1. Nordsrtöm M, Lindblad B, Bergvist D, et al. A prospective study of the incidence of deep vein thrombosis with a defined urban population. J Intern Med 1992; 232: 155-160. Go to original source... Go to PubMed...
  2. Heit JA. Venous thromboembolism, disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3: 1611-1617. Go to original source... Go to PubMed...
  3. Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013; 41: 462-468. Go to original source... Go to PubMed...
  4. Michielis JJ, Moosdorff W, mildred U Le, al. Diagnosis and treatment of DVT and prevention of DVT recurrence and the PTS: bridging the gap between DVT and PTS in the primary care setting or outpatient ward. Journal of Vascular Diagnostics 2014; 2: 1-14.
  5. SPC Pradaxa.
  6. Agnelli GI, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808. Go to original source... Go to PubMed...
  7. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708. Go to original source... Go to PubMed...
  8. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510. Go to original source... Go to PubMed...
  9. Konstantinides S, Torbicky A. Management of venous trombo-embolism: an update. Eur Heart J 2014; 35: 2855-2863. Go to original source... Go to PubMed...
  10. Black SA, Cohen AT. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach. Thromb Haemost 2015; 114: 660-669. Go to original source... Go to PubMed...
  11. Prandoni P, et al. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437-445. Go to PubMed...
  12. Dietcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003; 29: 247-258. Go to original source... Go to PubMed...
  13. Heit JA. Predicting the risks of venous thromboembolism recurrence. Am J Hematom 2012; 87: 63-67. Go to original source... Go to PubMed...
  14. Agnelli G, et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Eur Heart J 2014; 35(Abstrakt Suppl.): 994. Go to original source... Go to PubMed...
  15. Carrier M, et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SCC of the ISTH. J Thromb Haemost 2013; 11: 1760-1765. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.